ProCE Banner Events

Share

2023 PCE Oncology Fall Conferences - Solid Tumor Day

PCE, the national leader in continuing education for NPs and PAs, returns this November with our virtual Fall Oncology Conferences. These complimentary CE/CME meetings are tailored to meet the clinical needs and evolving scope of practice of NPs, PAs, and nurses who practice in oncology.
Register now and earn up to 4.0 CE/CME credits!

Nurses: 2.00 Nursing contact hours, including 2.00 hours of pharmacotherapy credit 

Physicians: maximum of 1.00 AMA PRA Category 1 Credit™

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurse Practitioners: 2.00 Nursing contact hours, includes 2.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Physician Assistants/Physician Associates: 2.00 AAPA Category 1 CME credits

This event has expired. No longer available for credits.

Who Should Attend

Oncology MDs, NPs, PharmDs, PAs, and RNs 

Time and location

Sunday, December 03, 2023

8:00 AM - 3:00 PM Eastern Time (ET)

Virtual

Faculty
Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

James M. Cleary, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Gastrointestinal Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Rasheda Persinger, MSN, AGNP-C, AOCNP

Medical Oncology Lead Nurse Practitioner
Sidney Kimmel Cancer Center Sibley Memorial Hospital
Johns Hopkins System
Washington, DC

Kathleen Madden, FNP, MSN, AOCNP, APHN

Melanoma Program
NYU Langone Perlmutter Cancer Center
New York, NY

Sakti Chakrabarti, MD

Attending GI Oncologist
UH Seidman Cancer Center
Cleveland, Ohio

Aileen Tangonan MacAndrew, RN, MSN, NP-C

Clinical Nurse Practitioner
UCLA Santa Monica Hematology-Oncology
Santa Monica, California

Sara Beeler, ARNP, AOCNP

Advanced Oncology Clinical Nurse Practitioner
Florida Cancer Specialists
Tampa, Florida

April Salama, MD

Associate Professor of Medicine
Division of Medical Oncology
Director, Melanoma Program
Duke Cancer Institute
Durham, North Carolina

Agenda

PCE Oncology – Solid Tumor Day (December 3, 2023)

8:00 AM – 8:55 AM: Combination Immunotherapy and Chemotherapy Regimens in NSCLC: Clinical Practice Recommendations for Oncology APPs - Rasheda Persinger, MSN, AGNP-C

8:55 AM – 9:00 AM: Break

9:00 AM – 10:00 AM:  Non-accredited Presentation Theater: TRUQAP + fulvestrant: A Novel 2L Treatment Option for HR+/HER2− aBC or mBC With PIK3CA/AKT1/PTEN Alterations Sponsored by Astra Zeneca - Sara Beeler, ARNP, AOCNP

10:00 AM – 10:55 AM: New Options in High-Risk Early Breast Cancer - Kevin Kalinsky, MD

10:55 PM – 11:00 AM: Break

11:00 AM – 12:00 PM: Non-accredited Presentation Theater: LONSURF® + bevacizumab for the Treatment of 3L Metastatic Colorectal Cancer Sponsored by Taiho Oncology - Aileen Tangonan MacAndrew, RN, MSN, NP-C 

12:00 PM – 12:55 PM: Maximizing Benefit with the Expanding Options for Gastric Cancer: Patient Selection and Management - James Cleary, MD

12:55 PM – 1:00 PM: Break

1:00 PM – 2:00 PM: Non-accredited Presentation Theater:  Introducing the First and Only Novel Targeted Therapy Approved for mCRC, Regardless of Mutation Status, in More Than a Decade Sponsored by Takeda Oncology - Sakti Chakrabarti, MD 

2:00 PM – 3:00 PM: Driving Improved Outcomes in Resectable Melanoma: Pathways for Optimized Adjuvant Immunotherapy Strategies - April Salama, MD

CME/CE Info

Program Overview
This live webinar program is designed for nurse practitioners, physician associates, and nurses who practice in oncology and will provide accredited education covering timely, expert-led, evidence-based education across a range of different cancers to advance the care of patients with cancer.

Target Audience
Oncology MDs, NPs, PharmDs, PAs, and RNs 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the latest evidence in the treatment of cancer including recommended biomarker testing, safety and efficacy of available therapies, and strategies to address health disparities
  • Integrate evidence-based strategies into practice for managing and individualizing the care of patients with cancer
  • Assess toxicities associated with treatments for cancer and apply recommended management strategies

 

Accreditation

Joint Accreditation Statement
A logo for a companyDescription automatically generated

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.0 contact hours.

     - New Options in High-Risk Early Breast Cancer: 1.0

     - Maximizing Benefit with the Expanding Options for Gastric Cancer: Patient Selection and Management: 1.0

Physician Associate Continuing Medical Education

A blue circle with white textDescription automatically generated

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

     - New Options in High-Risk Early Breast Cancer: 1.0

     - Maximizing Benefit with the Expanding Options for Gastric Cancer: Patient Selection and Management: 1.0

IPCE Credit Designation

A logo with a triangle in a circleDescription automatically generated

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

     - New Options in High-Risk Early Breast Cancer: 1.0

     - Maximizing Benefit with the Expanding Options for Gastric Cancer: Patient Selection and Management: 1.0


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

     - Combination Immunotherapy and Chemotherapy Regimens in NSCLC: Clinical Practice Recommendations for Oncology APPs: 1.0

     - Driving Improved Outcomes in Resectable Melanoma: Pathways for Optimized Adjuvant Immunotherapy Strategies: 1.0

Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     - Driving Improved Outcomes in Resectable Melanoma: Pathways for Optimized Adjuvant Immunotherapy Strategies: 1.0

Continuing Pharmacy Education

A black and white logoDescription automatically generated

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number:  JA4008176-0000-23-251-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

     - Driving Improved Outcomes in Resectable Melanoma: Pathways for Optimized Adjuvant Immunotherapy Strategies: 1.0

Physician Associate Continuing Medical Education

A blue circle with white textDescription automatically generated

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

     - Driving Improved Outcomes in Resectable Melanoma: Pathways for Optimized Adjuvant Immunotherapy Strategies: 1.0

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) and Partners for Advancing Clinical Education (PACE) require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO and PACE policy. CCO and PACE are committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Partners for Advancing Clinical Education (PACE) and Clinical Care Options, LLC

Combination Immunotherapy and Chemotherapy Regimens in NSCLC: Clinical Practice Recommendations for Oncology APPs
Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

New Options in High-Risk Early Breast Cancer
Supported by educational grants from Merck Sharp & Dohme LLC and AstraZeneca.

Maximizing Benefit with the Expanding Options for Gastric Cancer: Patient Selection and Management
Supported by an educational grant from Merck Sharp & Dohme LLC.

Driving Improved Outcomes in Resectable Melanoma: Pathways for Optimized Adjuvant Immunotherapy Strategies
Supported by an educational grant from Bristol Myers Squibb .